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Craig H. Moskowitz2Pertussis is a highly contagious respiratory infection characterized by prolonged cough and inspiratory
whoop. Despite widespread vaccination of children aged\7 years, its incidence is steadily increasing in ad-
olescents and adults, because of the known decrease in immunity following childhood immunization. In an
effort to reduce pertussis in adolescents and adults, 2 vaccines containing tetanus toxoid, reduced diphtheria
toxoid, and acellular pertussis (Tdap) (BOOSTRIX and Adacel) were licensed in 2005 for use in adolescents,
1 of which (Adacel) contains less pertussis toxoid (PT) for use in adults. This study assessed pertussis titers in
57 adult survivors of an autologous peripheral blood stem cell transplantation (PBSCT; median age, 37.5
years), 28 of whom were subsequently vaccinated with Tdap containing 2.5 mg of PT (Adacel). The median
time to Tdap administration was 3 years posttransplantation. Before vaccination, 87% of the patients lacked
pertussis immunity. Only 2 of the 28 patients developed a.2-fold response to PT following vaccination with
Tdap. These data suggest that autologous transplantation recipients are highly susceptible to pertussis and
that immunization with 2.5 mg of PT induces an inadequate response. Prospective trials evaluating BOOS-
TRIX, containing 8 mg/dose of PT (approved for adults in December 2008) are warranted in this vulnerable
population undergoing transplantation.
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Bordetella pertussis, a gram-negative coccobacillus,
causes an acute respiratory illness that in its classic
form is characterized by 1-2weeks of rhinorrhea and in-
termittent cough, followed by 4-6 weeks of spasmodic
cough, posttussive vomiting, and an inspiratory whoop
[1].Themajorityof adultswith thisdiseasehaveaparox-
ysmal cough lastingmore than 3weeks,with posttussive
vomiting reported in 27%-61% [2-4]. Up to 12%of in-
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6/j.bbmt.2009.07.018[3,5]. Despite widespread and effective vaccination of
children against pertussis since the 1940s, pertussis re-
mains endemic in the United States [1-4].
Over the last decade, the incidence of pertussis has
steadily increased in adolescents and adults to an
estimated incidence of 800,000-3.3 million cases/year
[1-4]. In 2005, in an effort to reduce pertussis in this
population, 2 vaccines containing tetanus toxoid
(TT), reduced diphtheria toxoid (DT), and acellular
pertussis toxoid (PT), BOOSTRIX (GlaxoSmithKline
Biologicals) and Adacel (sanofi Pasteur), were licensed
for use in the United States [6,7]. BOOSTRIX was ini-
tially approved for use in individuals aged 10-18 years,
and Adacel was approved for individuals aged 11-64
years. Although both vaccines contain similar amounts
of TT and DT, they differ in terms of PT content and,
up until recently, indicated age range [8]. In 2006, the
Advisory Committee on Immunization Practices
recommended that all adolescents and adults receive
a single dose of Tdap to replace the scheduled Td
booster [2,3].
There are limited data on pertussis immunity fol-
lowing hematopoietic cell transplantation (HCT)
and on the immunogenicity of Tdap in this patient
Table 1. Patient and Transplantation Characteristics
Total
(n5 57)
Tdap Recipients
(n5 28)
Age at PBSCT,
years, median (range)
37.5 (17.8-71.9) 42.6 (17.8-71.9)
Age at vaccination,
years, median (range)
45.1 (20.2-73.2)
Diagnosis, n
HL 29 12 (11 evaluable)
Biol Blood Marrow Transplant 15:1538-1542, 2009 1539TDAP following transplantationpopulation [9]. In the present study, we assessed resid-
ual pertussis titers in 57 adult survivors of autologous
peripheral blood stem cell transplantation (PBSCT),
as well as the response of the first 28 patients vacci-
nated with Adacel. The effect of diagnosis, age at
transplantation, time to vaccination, and receipt of
the CD20 monoclonal antibody (mAb) rituximab on
pertussis titers and vaccine response was assessed.NHL 25 15 (14 evaluable)
Oligodendroglioma 3 1 (1 evaluable)
Cytoreduction, n
BEAM 21 13
CBV 15 (8 with involved
field radiation
therapy)
8
TLI/Cy/VP 11 1
Busulfan/thiotepa 3 2
Total body
irradiation–containing
regimen
4 1
Other 4 3
CD34+ cells/kg,
median (range)
5.4 (1.2-26.0) 106 4.65 (1.2-26) 106
PBSCT indicates peripheral blood stem cell transplantation; HL, Hodg-
kin lymphoma; NHL, non-Hodgkin lymphoma; BEAM, carmustine, eto-
poside, cytarabine, and melphalan; TLI, total lymphoid irradiation;
CBV, cerebral blood volume; Cy, cyclophosphamide.MATERIALS AND METHODS
Patients
A waiver of authorization to conduct this study was
approved by Memorial Sloan-Kettering Cancer Cen-
ter’s Institutional Review Board. The medical records
of adult patients who remained disease-free for 1 year
after autologous PBSCT performed between January
1, 2000, and June 1, 2007, for the treatment ofHodgkin
lymphoma (HL), non-Hodgkin lymphoma (NHL), or
oligodendroglioma were reviewed for assessment of
pertussis titers and immunization with Tdap. Dates of
vaccination and prevaccine and postvaccine titers were
obtained from a prospectively maintained database
and confirmed by retrospective chart review. Titers
against PT and filamentous hemagglutinin (FHA)
were available in 57 patients, 28 of whom had been vac-
cinated with Tdap (Adacel). Patient and transplant de-
mographics are shown in Table 1. The patients
underwent transplantation for HL (n5 29), NHL
(n5 25), or oligodendroglioma (n5 3). The median
age at transplantation was 37.5 years (range, 17.8-71.9
years). Patients with NHL were significantly older
than patients withHL (median age, 54 years vs 34 years;
P\ .001). The most commonly used transplantation
conditioning regimens were carmustine, etoposide,
cytarabine, and melphalan (BEAM; n5 21) and cyclo-
phosphamide, carmustine, etoposide with (n5 8) or
without (n5 7) involved field radiation therapy.
Twenty-one of 25 patients who underwent transplanta-
tion forNHLreceived theCD20mAb rituximabbefore
transplantation (n5 4), after transplantation (n5 8), or
both before and after transplantation (n5 9). All pa-
tients received autologous PBSC obtained aftermobili-
zationwith ifosfamide, carboplatin, and etoposide. The
median CD341 cell dose was 5.4 106/kg (range, 1.2-
26.0 106/kg).
All patients receivedAdacel, approved for individuals
aged 11-64 years, containing 2.5 mg of detoxified PT,
5 mg of FHA, 3 mg of pertactin, 5 mg of fimbriae types
2 and 3, 5 Lf (limit of flocculation unit) of TT, and
2 Lf of DT.
Antibody Titers
Antibodies against TT (anti-TT), DT (anti-DT),
PT (anti-PT), and FHA were measured by enzyme-
linked immunosorbent assay (ELISA). The lower limitof detection was for 0.1 IU/mL for TT, 0.01 IU/mL
for DT, 1 IU/mL for PT, and 1 IU/mL for FHA.
Anti-TT and anti-DT titers were considered positive
if. 0.15 IU/mL and. 0.01 IU/mL, respectively. Al-
though there is no known protective level of anti-PT
immunity [1], in most studies, a value of 5-8 IU/mL
is considered positive [10-12]. Thus, in this study,
a positive vaue was defined as. 5 IU/mL. Response
to TT and DT was defined as a 4-fold rise in titer
or seroconversion; partial response was defined as
a$ 2- and\4-fold rise in titer. Response to PT was
defined as$ 2-fold increase in anti-PT antibody level.Statistical Analysis
The Fisher exact test for qualitative variables and
the Wilcoxon rank-sum test for quantitative variables
were used for comparisons between groups. Only P
values\ .05 were considered statistically significant.RESULTS
PT and TT titers were assessed in 57 patients at
a median of 38 months (range, 10-90.7 months) after
transplantation. Only 13.5% of the patients had an
anti-PT. 5 IU/mL (Figure 1); approximately 50%
had an undetectable titer (\ 1 IU/mL). The median
anti-PTand anti-FHA titer was 1 IU/mLand 8 IU/mL,
respectively. There were no significant differences
in titers based on age at transplantation, years post-
transplantation, or diagnosis of HL versus NHL.
Nineteen of the patients (33%) lacked protective
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Figure 1. Pertussis titers after autologous PBSCT. The horizontal
dashed line represents the lower limit of positive titers (. 5 IU/mL).
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for residual diphtheria immunity were seronegative.
Twenty-eight of the 57 patients (49%) were im-
munized with Adacel. In all 28 patients, both pretrans-
plantation and postransplantation PT and TT titers
were obtained. The median age at vaccination was
45.1 years (range, 20.2-73.2 years). The median time
to vaccination was 36.0 months (range, 15.6-99.9
months) after transplantation. The median time to as-
sess vaccine response was 87.5 days (range, 28-224
days) after Tdap administration. There was no signif-
icant difference in the time to vaccination in patients
undergoing transplantation for HL or NHL (35
months vs 40 months). The median time between vac-
cination and the last dose of rituximab in the patients
with NHL was 31.3 months. No patient reported a se-
rious adverse reaction, including significant erythema,
induration, or fever. 38.3C. Before Tdap adminis-
tration, 77% of the patients lacked immunity against
pertussis, 24% lacked immunity against tetanus, and
28% lacked immunity against diphtheria.
Twenty-six of the 28 patients (93%) did not re-
spond to PT. Two patients, 1 with an oligodendro-
glioma (aged 35 years) and 1 with NHL (aged 63
years), vaccinated 2.5 and 8.5 years posttransplanta-
tion, respectively, exhibited a. 2-fold response toHL, TT response, n=12
10
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Figure 2. Tetanus titers before and after Tdap administration in patients after
seroconverted or developed a. 3-fold rise in tetanus antibody. NonrespondePT. No patient with HL or any patient with NHL
who received posttransplantation rituximab responded
to PT or FHA. There was no difference in response
rate when pertussis titers were assessed 1-3 months
or 3-7 months after Tdap administration.
Despite the very poor response toPTandFHA, 6 of
12 patients withHLdeveloped a partial (n5 1) or com-
plete (n5 5) response (PR, CR) to TT, and 6 of 12 had
a CR to DT. Response in patients with NHL, the ma-
jority of whom received pretransplantation and post-
transplantation rituximab, was poor. Only 3 of 15
patients with NHL responded to TT (Figure 2). Of
the 11 patients with NHL evaluated for response to
DT,only 3 responded.Therewas a trend towardpoorer
TT response in patients undergoing transplantation for
NHL compared with those doing so for HL (P5 .09).
The difference in DT response between these 2 groups
was not significant (P5 .18).DISCUSSION
Disease-free survival (DFS) following autologous
HCT for HL andNHL continues to improve, with in-
creasing numbers of survivors reentering the work-
place or school and caring for infants and young
children [13-15]. Worldwide, more than 30,000 autol-
ogous HCTs are performed each year [16]. Without
effective immunization practices, these patients are at
risk for morbidity and mortality resulting from vaccine
preventable disease and act as reservoirs to spread dis-
ease. In adults, particularly those over the age of 50
years, pertussis is associated with significant morbid-
ity, including pneumonia and the need for hospitaliza-
tion [3]. A study of 964 adults with pertussis, aged. 65
years found that 6% developed pneumonia and 12%
required hospitalization [5]. Infected adults represent
the major vector of pertussis for susceptible infants,
the population with the highest morbidity associated
with this disease [3]. Among 6114 children withNHL, TT response, n=15
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PBSCT for HL or NHL. The dashed lines represent patients who either
rs are indicated by solid lines.
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for Disease Control and Prevention between 2000 and
2004, 62% required hospitalization and 13% devel-
oped pneumonia [3].
This study, the first to evaluate pertussis immunity
following autologous HCT, demonstrates that long-
term survivors of autologous PBSCT for lymphoma
are highly susceptible to pertussis. In a study of healthy
individuals aged 30-60 years, Launay et al. [11] re-
ported that approximately 30% had anti-PT titers of
20-124 IU/mL, compared with\2% in our study.
This indicates either a lack of past infection in our pa-
tient population or, more likely, transplantation-re-
lated loss of pertussis immunity following childhood
vaccination. More than 30% of our study population
lacked detectable TT or DT titers posttransplanta-
tion. Studies of residual tetanus immunity after autol-
ogous HCT have shown variable results. Whereas
Hammarstrom et al. [17] demonstrated that 71%
(37/52) of autologous bone marrow (BM) recipients
and 52% (20/38) of PBSC recipients were susceptible
to tetanus by 1 year posttransplantation, none of the 35
adult recipients reported by Nordøy et al. [18] had be-
come seronegative for tetanus when evaluated at 4-10
years posttransplantation, but only 36% of the 35 pa-
tients retained immunity against diphtheria. Clearly,
differences in age at transplantation, underlying diag-
nosis, dose intensity, duration of treatment before
transplantation, and the transplantation conditioning
regimen influence the duration of residual titers as
well as response to vaccination. Nevertheless, our
study, as well as those of others [19], demonstrate
poor response to a single Td or TT vaccine after autol-
ogous HCT. Gandhi et al. [19] reported that only 8 of
24 autologous PBSCT and 1 of 9 autologous BM
transplantation recipients responded to a single teta-
nus immunization. These findings emphasize the
need to give more than one tetanus- and diphtheria-
containing vaccine to all recipients of autologous
HCT recipients, as recommended in current post-
transplantation vaccine guidelines [20,21].
The pertussis response in our study was poor re-
gardless of age, diagnosis, or time posttransplantation.
The lack of response to Tdap containing 2.5 ug of PT
is likely due to insufficient numbers and/or function of
antigen-specific memory T and/or B cells. In Decem-
ber 2008, the Tdap vaccine BOOSTRIX, containing
8 ug of PT, was approved for adults, extending its orig-
inal indication beyond adolescence [8]. Our data sug-
gest that this vaccine should be tested in autologous
HCT recipients because of its higher PT content.
Posttransplantation, even higher doses of PT and/or
several immunizations may be needed to induce
immunity. Although more than one vaccination with
Tdap is not currently recommended for healthy indi-
viduals, vaccines containing. 8 ug of PT have been
used safely in adults. In a study of 261 pediatric healthand child care workers immunized with a single mono-
valent pertussis vaccine containing 25 mg of PT, long-
lasting immunity was achieved in the absence of
serious adverse events [10]. Median IgG anti-PT levels
of 76, 71, 71, and 63 EU/mL were observed at 1, 2, 3,
and 4 years, respectively, following a single dose. Pro-
spective trials testing strategies to effectively immunize
the growing numbers of autologous HCT survivors
against pertussis are needed.ACKNOWLEDGMENTS
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